Greenwich Historical Balance Sheet

GLSI Stock

USD 11.69 0.01 0.09%

Trend analysis of Greenwich Lifesciences balance sheet accounts such as Total Current Liabilities of 251.7 K or Total Stockholder Equity of 11.5 M provides information on Greenwich Lifesciences' total assets, liabilities, and equity, which is the actual value of Greenwich Lifesciences to its prevalent stockholders. By breaking down trends over time using Greenwich Lifesciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

About Greenwich Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Greenwich Lifesciences at a specified time, usually calculated after every quarter, six months, or one year. Greenwich Lifesciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Greenwich Lifesciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Greenwich currently owns. An asset can also be divided into two categories, current and non-current.

Greenwich Lifesciences Balance Sheet Chart

As of now, Greenwich Lifesciences' Net Tangible Assets are increasing as compared to previous years. The Greenwich Lifesciences' current Cash is estimated to increase to about 14 M, while Total Current Liabilities is projected to decrease to under 251.7 K.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Total Assets

Total assets refers to the total amount of Greenwich Lifesciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Greenwich Lifesciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Greenwich Lifesciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Greenwich Lifesciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Greenwich Lifesciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Greenwich Lifesciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.As of now, Greenwich Lifesciences' Net Tangible Assets are increasing as compared to previous years. The Greenwich Lifesciences' current Cash is estimated to increase to about 14 M, while Total Current Liabilities is projected to decrease to under 251.7 K.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	42.1K	258.9K	233.0K	311.1K
Total Assets	13.5M	7.0M	8.0M	14.0M

Other Current Liab Total Assets

Greenwich Lifesciences balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Intangible Assets	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Short Term Debt
Total Assets		-0.18	-0.28	0.97	-0.22	0.81	-0.98	-0.47	-0.3	1.0	-0.59	1.0	0.48	0.53	-0.73	0.81	-0.73	0.97	1.0	0.75	1.0	-0.59	0.77	-0.82	0.85	-0.82
Other Current Liab	-0.18		0.89	-0.25	0.25	-0.46	0.15	0.61	0.58	-0.18	0.59	-0.18	-0.68	-0.52	0.35	-0.46	0.35	-0.25	-0.18	-0.37	-0.21	0.59	-0.39	0.5	-0.49	0.5
Total Current Liabilities	-0.28	0.89		-0.31	0.48	-0.56	0.2	0.72	0.88	-0.28	0.69	-0.28	-0.63	-0.69	0.34	-0.53	0.35	-0.31	-0.28	-0.38	-0.3	0.69	-0.42	0.6	-0.59	0.6
Total Stockholder Equity	0.97	-0.25	-0.31		-0.27	0.9	-0.95	-0.62	-0.28	0.97	-0.73	0.97	0.64	0.62	-0.87	0.91	-0.87	1.0	0.97	0.89	0.97	-0.73	0.9	-0.9	0.92	-0.9
Other Liab	-0.22	0.25	0.48	-0.27		-0.52	0.03	0.61	0.51	-0.22	0.62	-0.22	-0.58	-0.73	0.42	-0.41	0.43	-0.27	-0.22	-0.41	-0.22	0.62	-0.4	0.37	-0.38	0.37
Net Tangible Assets	0.81	-0.46	-0.56	0.9	-0.52		-0.74	-0.89	-0.52	0.81	-0.95	0.81	0.85	0.85	-0.94	0.98	-0.94	0.9	0.81	0.96	0.82	-0.95	0.97	-0.98	0.98	-0.98
Net Debt	-0.98	0.15	0.2	-0.95	0.03	-0.74		0.37	0.22	-0.98	0.5	-0.98	-0.39	-0.43	0.68	-0.77	0.68	-0.95	-0.98	-0.71	-0.98	0.5	-0.73	0.79	-0.8	0.79
Retained Earnings	-0.47	0.61	0.72	-0.62	0.61	-0.89	0.37		0.63	-0.47	0.98	-0.47	-0.91	-0.83	0.83	-0.85	0.83	-0.62	-0.47	-0.83	-0.48	0.98	-0.84	0.84	-0.84	0.84
Accounts Payable	-0.3	0.58	0.88	-0.28	0.51	-0.52	0.22	0.63		-0.3	0.6	-0.3	-0.41	-0.68	0.22	-0.48	0.23	-0.28	-0.3	-0.29	-0.32	0.6	-0.33	0.57	-0.56	0.57
Cash	1.0	-0.18	-0.28	0.97	-0.22	0.81	-0.98	-0.47	-0.3		-0.59	1.0	0.48	0.53	-0.73	0.81	-0.73	0.97	1.0	0.75	1.0	-0.59	0.77	-0.83	0.85	-0.83
Non Current Assets Total	-0.59	0.59	0.69	-0.73	0.62	-0.95	0.5	0.98	0.6	-0.59		-0.59	-0.93	-0.89	0.89	-0.92	0.89	-0.73	-0.59	-0.9	-0.6	1.0	-0.91	0.91	-0.9	0.91
Cash And Short Term Investments	1.0	-0.18	-0.28	0.97	-0.22	0.81	-0.98	-0.47	-0.3	1.0	-0.59		0.48	0.53	-0.73	0.81	-0.73	0.97	1.0	0.75	1.0	-0.59	0.77	-0.83	0.85	-0.83
Common Stock Total Equity	0.48	-0.68	-0.63	0.64	-0.58	0.85	-0.39	-0.91	-0.41	0.48	-0.93	0.48		0.79	-0.87	0.83	-0.87	0.64	0.48	0.86	0.49	-0.93	0.86	-0.78	0.78	-0.78
Common Stock Shares Outstanding	0.53	-0.52	-0.69	0.62	-0.73	0.85	-0.43	-0.83	-0.68	0.53	-0.89	0.53	0.79		-0.72	0.83	-0.72	0.62	0.53	0.77	0.54	-0.89	0.78	-0.82	0.78	-0.82
Non Current Liabilities Total	-0.73	0.35	0.34	-0.87	0.42	-0.94	0.68	0.83	0.22	-0.73	0.89	-0.73	-0.87	-0.72		-0.94	1.0	-0.87	-0.73	-0.99	-0.73	0.89	-0.98	0.88	-0.89	0.88
Other Stockholder Equity	0.81	-0.46	-0.53	0.91	-0.41	0.98	-0.77	-0.85	-0.48	0.81	-0.92	0.81	0.83	0.83	-0.94		-0.94	0.91	0.81	0.97	0.82	-0.92	0.98	-0.99	0.98	-0.99
Total Liab	-0.73	0.35	0.35	-0.87	0.43	-0.94	0.68	0.83	0.23	-0.73	0.89	-0.73	-0.87	-0.72	1.0	-0.94		-0.87	-0.73	-0.99	-0.74	0.89	-0.99	0.89	-0.89	0.89
Net Invested Capital	0.97	-0.25	-0.31	1.0	-0.27	0.9	-0.95	-0.62	-0.28	0.97	-0.73	0.97	0.64	0.62	-0.87	0.91	-0.87		0.97	0.89	0.97	-0.73	0.9	-0.9	0.92	-0.9
Total Current Assets	1.0	-0.18	-0.28	0.97	-0.22	0.81	-0.98	-0.47	-0.3	1.0	-0.59	1.0	0.48	0.53	-0.73	0.81	-0.73	0.97		0.75	1.0	-0.59	0.77	-0.83	0.85	-0.83
Capital Stock	0.75	-0.37	-0.38	0.89	-0.41	0.96	-0.71	-0.83	-0.29	0.75	-0.9	0.75	0.86	0.77	-0.99	0.97	-0.99	0.89	0.75		0.76	-0.9	1.0	-0.93	0.92	-0.93
Net Working Capital	1.0	-0.21	-0.3	0.97	-0.22	0.82	-0.98	-0.48	-0.32	1.0	-0.6	1.0	0.49	0.54	-0.73	0.82	-0.74	0.97	1.0	0.76		-0.6	0.78	-0.84	0.86	-0.84
Intangible Assets	-0.59	0.59	0.69	-0.73	0.62	-0.95	0.5	0.98	0.6	-0.59	1.0	-0.59	-0.93	-0.89	0.89	-0.92	0.89	-0.73	-0.59	-0.9	-0.6		-0.91	0.91	-0.9	0.91
Common Stock	0.77	-0.39	-0.42	0.9	-0.4	0.97	-0.73	-0.84	-0.33	0.77	-0.91	0.77	0.86	0.78	-0.98	0.98	-0.99	0.9	0.77	1.0	0.78	-0.91		-0.95	0.94	-0.95
Short Long Term Debt Total	-0.82	0.5	0.6	-0.9	0.37	-0.98	0.79	0.84	0.57	-0.83	0.91	-0.83	-0.78	-0.82	0.88	-0.99	0.89	-0.9	-0.83	-0.93	-0.84	0.91	-0.95		-0.99	1.0
Current Deferred Revenue	0.85	-0.49	-0.59	0.92	-0.38	0.98	-0.8	-0.84	-0.56	0.85	-0.9	0.85	0.78	0.78	-0.89	0.98	-0.89	0.92	0.85	0.92	0.86	-0.9	0.94	-0.99		-0.99
Short Term Debt	-0.82	0.5	0.6	-0.9	0.37	-0.98	0.79	0.84	0.57	-0.83	0.91	-0.83	-0.78	-0.82	0.88	-0.99	0.89	-0.9	-0.83	-0.93	-0.84	0.91	-0.95	1.0	-0.99

Click cells to compare fundamentals

Greenwich Lifesciences Account Relationship Matchups

Greenwich Lifesciences balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	28.7M	27.2M	13.5M	7.0M	8.0M	14.0M
Other Current Liab	770.3K	164.3K	42.1K	258.9K	233.0K	311.1K
Total Current Liabilities	1.0M	385.2K	262.9K	294.4K	265.0K	251.7K
Total Stockholder Equity	27.6M	26.8M	13.2M	6.7M	7.7M	11.5M
Net Debt	(28.7M)	(27.2M)	(13.5M)	(7.0M)	(6.3M)	(6.6M)
Retained Earnings	(29.1M)	(33.6M)	(41.5M)	(50.4M)	(45.3M)	(47.6M)
Accounts Payable	730.3K	275.2K	220.8K	35.5K	31.9K	30.3K
Cash	28.7M	27.2M	13.5M	7.0M	8.0M	14.0M
Non Current Assets Total	16.2K	12.6K	9.0K	5.4K	4.9K	4.6K
Cash And Short Term Investments	28.7M	27.2M	13.5M	7.0M	8.0M	14.0M
Common Stock Shares Outstanding	12.7M	12.9M	12.9M	12.8M	14.8M	13.8M
Liabilities And Stockholders Equity	28.7M	27.2M	13.5M	7.0M	8.0M	14.0M
Other Stockholder Equity	56.7M	60.5M	54.7M	57.1M	65.6M	49.2M
Total Liab	1.0M	385.2K	262.9K	294.4K	265.0K	251.7K
Net Invested Capital	27.6M	26.8M	13.2M	6.7M	7.7M	11.5M
Total Current Assets	28.7M	27.2M	13.5M	7.0M	8.0M	14.0M
Capital Stock	10.4K	12.7K	13.1K	12.8K	14.8K	11.8K
Net Working Capital	27.6M	26.8M	13.2M	6.7M	7.7M	13.3M
Intangible Assets	16.2K	12.6K	9.0K	5.4K	4.9K	4.6K
Common Stock	8.5K	12.7K	13.1K	12.8K	14.8K	11.0K

Currently Active Assets on Macroaxis

CRM	Salesforce
C	Citigroup
GM	General Motors
WD	Walker Dunlop
MSFT	Microsoft

When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:

How To Invest In Greenwich

Details

Is Greenwich Stock a good investment?

Details

What is Greenwich Lifesciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.81)

Return On Assets

(0.90)

Return On Equity

(1.52)

The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Greenwich Historical Balance Sheet

About Greenwich Balance Sheet Analysis

Greenwich Lifesciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Greenwich Lifesciences balance sheet Correlations

Greenwich Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Greenwich Lifesciences balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash

Short Term Debt	- 0.99	Current Deferred Revenue
Current Deferred Revenue	- 0.99	Short Long Term Debt Total
Common Stock	- 0.99	Total Liab
Capital Stock	- 0.99	Total Liab
Short Term Debt	- 0.99	Other Stockholder Equity
Short Long Term Debt Total	- 0.99	Other Stockholder Equity